Meeting News CoverageVideo

VIDEO: Veltassa demonstrates lower potassium levels in patients with hyperkalemia

AUSTIN, Texas — At the National Kidney Foundation Spring Clinical Meetings, Matthew R. Weir, MD, spoke about results of a study that measured the efficacy and safety of Veltassa for patients with hyperkalemia.

The results presented in a poster here were from a pooled analysis of 653 patients from the OPAL-HK, AMETHYST-DN and TOURMALINE phase 3 clinical studies. Overall, 98% of the patients had hypertension and 93% of patients were taking renin-angiotensin-aldosterone system (RAAS)-inhibitor therapy.

Weir said results demonstrate the utility of the new approach to control hyperkalemia, as Veltassa (patiromer, Relypsa Inc.) consistently reduced potassium levels in the patients studied, including patients on RAAS-inhibitor therapy.

AUSTIN, Texas — At the National Kidney Foundation Spring Clinical Meetings, Matthew R. Weir, MD, spoke about results of a study that measured the efficacy and safety of Veltassa for patients with hyperkalemia.

The results presented in a poster here were from a pooled analysis of 653 patients from the OPAL-HK, AMETHYST-DN and TOURMALINE phase 3 clinical studies. Overall, 98% of the patients had hypertension and 93% of patients were taking renin-angiotensin-aldosterone system (RAAS)-inhibitor therapy.

Weir said results demonstrate the utility of the new approach to control hyperkalemia, as Veltassa (patiromer, Relypsa Inc.) consistently reduced potassium levels in the patients studied, including patients on RAAS-inhibitor therapy.

    See more from National Kidney Foundation Spring Clinical Meetings